Hepatocellular Carcinoma Registry for Turkey (3K Trial)
Profile of the Hepatocellular Carcinoma Patients in Turkey
2 other identifiers
observational
600
1 country
1
Brief Summary
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators. It is designed in order to determine the general profile of HCC patients in Turkey. Socio-demographic characteristics, family history, medical history and treatment pattern of HCC patients will be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 2011
CompletedFirst Posted
Study publicly available on registry
November 17, 2011
CompletedStudy Start
First participant enrolled
August 13, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 12, 2018
CompletedJuly 5, 2019
July 1, 2019
4.9 years
November 2, 2011
July 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Descriptive analysis of HCC risk factors
i.e. smoking and alcohol consumption status; family history for hepatitis, HCC, and other malignancies; history of hepatic disease and blood transfusion; concomitant diseases; treatments applied
Baseline
Descriptive analysis of clinical profile of newly diagnosed HCC patients
Baseline
Secondary Outcomes (7)
Number of participants with underlying liver disease and family history
Baseline
Treatment options as applied by doctors to HCC patients
Up to approximately 5 years
Overall survival time since diagnosis
Up to approximately 5 years
Number of participants with adverse events
Up to approximately 5 years
Descriptive analysis of demographic characteristics of HCC patients
Baseline
- +2 more secondary outcomes
Study Arms (1)
Group 1
Interventions
Eligibility Criteria
Patients that are diagnosed with hepatocellular carcinoma in last 3 months
You may qualify if:
- To be diagnosed with hepatocellular carcinoma in last 3 months
- To be older than 18 years old
- To sign informed consent form (ICF)
You may not qualify if:
- Patients that does not sign or withdraw informed consent form.
- According to investigator's opinion; existence of any situation/condition that will significantly complicate patient follow up.
- Currently or previously taking part in 3K observational study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (1)
Unknown Facility
Multiple Locations, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2011
First Posted
November 17, 2011
Study Start
August 13, 2012
Primary Completion
June 30, 2017
Study Completion
July 12, 2018
Last Updated
July 5, 2019
Record last verified: 2019-07